Clinical Trial Update: Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing sorafenib plus erlotinib versus erlotinib alone in previously treated advanced non-small-cell lung cancer has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Sorafenib (Sorafenib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-09-21